Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNFR1, PIGF2, Activin A, uE3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.

Abstract: A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.

Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.

Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNFR1, PIGF2, Activin A, uE3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.

Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNR1, P1GF2, Activin A, Ue3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.

Abstract: A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.

Abstract: A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.

Abstract: A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.

Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.

Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCG-beta, and at least one biomarker selected from FSTL3, sTNR1, P1GF2, Activin A, Ue3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.

Abstract: A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing pre-eclampsia.

Abstract: A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing pre-eclampsia.

Abstract: A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.

Abstract: A method for the evaluation of sample activities in multidetector liquid scintillation counters. All prepared quench curve standards are measured only in one reference detector in order to establish the relationship between the quench levels and the counting efficiencies. In addition, only two of the standards, preferably those with lowest and highest level of quench, are measured in every detector in order to establish the relationship of the quench levels between the reference detector and any other detector and in order to establish the relationship of the counting efficiencies between the reference detector and any other detector. The activities of unknown samples are evaluated by utilizing the predetermined relationships.

Abstract: The object of the invention is a method for the evaluation of sample activities in multidetector liquid scintillation counters. According to the invention the memory of said apparatus is provided with a theoretically derived model for each isotope between the counting efficiencies and the quench levels. In addition at least one standard is measured in each detector in order to establish relationships between said theoretical model and each detector. The activities of an unknown sample is evaluated by utilizing said theoretical model and said relationship.

Abstract: Liquid scintillation counter includes a memory having stored spectra of known counting efficiencies and known levels of quench, for the isotopes to be meansured. A device extracts from the spectra, using the determined quench level value for each of the N isotopes, a reference spectrum representing a pure isotope spectrum at the determined quench level. A device determines for each extracted reference spectrum a factor by which the extracted reference spectrum is to be multiplied in order to fit the sum of the multiplied reference spectra to the sample spectrum. Each factor is directly related to the amount of each isotope in the sample.

Abstract: Liquid scintillation counter includes a memory having stored spectra of known counting efficiencies and known levels of quench, for isotopes to be measured. A device extracts from the spectra, by using the determined quench level value for each of the N isotopes, a reference spectrum representing a pure isotope spectrum at the predicted quench level. A device determines for each extracted reference spectrum a factor by which the extracted reference spectrum is to be multiplied in order to fit the sum of the multiplied reference spectra to the sample spectrum. Each factor is directly related to the amount of each isotope in the sample. A device computes a goodness-of-fit value and predicts a new value for the quench level based on this goodness-of-fit value. A method in liquid scintillation counter includes predicting a first value of the quench level of the scintillation sample.

Abstract: To produce a quench calibration function for a liquid scintillation counter having stored a basic correlation between a quantity to be quench calibrated and a quench index, the value of the quantity to be quench calibrated and the value of the quench index for at least one reference sample is measured by measuring means from said basic correlation, the value of the quantity to be quench calibrated for the measured value of the quench index for each reference sample is evaluated by evaluating means. Then the difference or ratio between the measured and the calculated values of the quantity to be quench calibrated for each reference sample is calculated by calculating means, whereupon said calculated difference or ratio as a function of quench index is approximated by approximating means, and said basic correlation and said function of quench of quench index are combined into the quench calibration function by combining means.

Abstract: In a liquid scintillation counter the light output from a liquid scintillation sample containing radioactive isotopes of unknown activity is measured by means of a detector. A pulse height analyzer having discriminators that are combined to define pulse height windows, is connected to the detector for measuring and temporarily storing count rates for each of the windows. Moreover, there are means for determining a value for the quench level of the sample. According to the invention the number of pulse height windows is at least N+1, when the number of isotopes is N,N being .gtoreq.2. There are memory means for storing for each of said windows representations of counting intensities determined by measuring calibration samples of each isotope at different levels of quench.